Microdosing THC for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Microdosing THC for Health & Longevity

Created on 08/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Very small amounts of the main cannabis compound, too little to intoxicate. The strongest human evidence — small improvements in pain and sleep — comes from trials in people with long-standing pain that mostly used larger amounts. Brain-aging claims rest almost entirely on animal work. Dependence, heart and thinking signals are real; much of the research is commercially funded. (Full Review)

Protocol

Standard approach — minimum effective dose titration
1 mg, rising by 1 mg
Two days' abstinence resets receptor sensitivity; escalation stops at the last dose below a mild perceptible effect.
Best time of day
Evening, 60–120 min before bed
Confines impairment to hours when it does not matter; daytime dosing carries driving and fall risk across the 4–8 hour oral window.
Half-life and dosing frequency
No escalation faster than every 3 days
Half-life is 20–30 hours in occasional users; daily dosing accumulates for 3–5 days before levels stabilize.
Time to effect
Pain benefit
1–2 weeks
Trials showing the benefit mostly used doses above the microdosing range.
Sleep-onset benefit
First night
Tolerance develops within days to weeks of nightly use.
Cognitive aging effect
Never demonstrated in a person
On the rodent timelines any purported effect would require weeks to months.

Benefits

Contraindications
  • Personal or first-degree family history of schizophrenia, schizoaffective or bipolar I disorder, or cannabis-induced psychosis
  • Pregnancy and lactation
  • Age under 25
  • Recent myocardial infarction (under 90 days), unstable angina or uncontrolled arrhythmia
  • New York Heart Association Class III or IV heart failure
  • Child-Pugh Class B or C liver impairment
  • Active substance use disorder
  • Safety-critical or federally drug-tested occupations (including Department of Transportation)
  • Competitive athletes under in-competition anti-doping testing
  • Surgery scheduled within 72 hours
    •
Key Interactions
  • Anticoagulants (warfarin)
  • Nervous-system depressants (benzodiazepines, opioids, sleep drugs, gabapentinoids, barbiturates)
  • CYP3A4 inhibitors (ketoconazole, ritonavir, verapamil, grapefruit juice)
  • CYP3A4 and CYP2C9 inducers (rifampin, carbamazepine, phenytoin, St. John's wort)
  • Other CYP2C9 substrates (phenytoin, glipizide, celecoxib, losartan)
  • Immunosuppressants (tacrolimus, sirolimus)
  • Anticholinergics and tricyclic antidepressants (amitriptyline, oxybutynin, scopolamine)
  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine)
  • Alcohol
  • Sedating supplements (melatonin, valerian, kava, ashwagandha)
  • Cannabidiol
  • Blood-pressure-lowering supplements (dietary nitrate, hibiscus, garlic, omega-3)
  • Other interventions (sauna, prolonged fasting, intense exercise)
    •

Risk & Side Effects

  • High: Acute cognitive and psychomotor impairment; dizziness, lightheadedness and falls; sedation, somnolence and next-day grogginess; increased heart rate and acute cardiovascular strain
  • Medium: Major adverse cardiovascular events with regular use; cannabis use disorder and psychological dependence; withdrawal on discontinuation; anxiety, paranoia and psychosis-like effects
  • Low: Interaction-mediated harm; disrupted sleep architecture with chronic nightly use; reproductive and hormonal effects; cannabinoid hyperemesis syndrome
  • Speculative: Accelerated long-term cognitive aging; blunted training adaptation; persistent receptor downregulation reducing baseline signaling

Monitoring

Marker Target Why
Resting heart rate 50–65 bpm THC's most reliable physical effect is a faster heart rate
Blood pressure, seated and standing Under 120/80 mmHg seated; postural drop under 20/10 mmHg Widened blood vessels and postural drop are the main mechanism behind falls
Apolipoprotein B Under 80 mg/dL Direct count of the particles that drive artery disease
High-sensitivity C-reactive protein (hs-CRP) Under 1.0 mg/L Tests the claimed anti-inflammatory benefit
Fasting insulin 2–5 µIU/mL Tests the claimed insulin-sensitivity benefit and the cost of appetite-driven intake
Fasting glucose 75–86 mg/dL Detects metabolic drift from increased energy intake
Hemoglobin A1c (HbA1c) 4.8–5.2% Three-month average blood sugar exposure
Alanine aminotransferase (ALT) 10–26 U/L in men, 8–22 U/L in women The liver clears THC via CYP2C9 and CYP3A4; impairment raises exposure
International normalized ratio (INR) Within the individual's therapeutic target Warfarin only: CYP2C9 inhibition by THC can cause bleeding

Cadence: Baseline before the first dose. Heart rate and standing blood pressure at each escalation, then weekly for a month; international normalized ratio weekly for 4 weeks on warfarin; full panel at 3 months, then every 6–12 months.

Qualitative Assessment

  • Morning clarity: a 1–10 rating before the first coffee; downward drift signals too high a dose
  • Sleep onset and continuity: minutes to fall asleep and awakenings; benefit lost after 2–3 weeks indicates tolerance
  • Dream recall: absence suggests suppressed rapid-eye-movement sleep; vivid dreams during a break indicate rebound
  • Perceptual clarity: altered time, detachment or unease means the dose is above the microdose threshold
  • Cognitive performance: a timed digit-symbol or reaction-time test monthly before dosing
  • Appetite and body composition: weekly weight and monthly waist circumference
  • Training quality: perceived effort at a fixed workload and weekly training volume
  • Ease of taking a break: difficulty completing a planned 2-day pause indicates dependence is forming
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.